Clinical Trial: Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)

U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07868939) titled 'Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)' on Oct. 05.

Brief Summary: This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI >= 30 kg/m2) or overweight (BMI >= 27 kg/m2) adults with Type 2 Diabetes Mellitus.

Study Start Date: Oct. 16

Study Type: INTERVENTIONAL

Condition: Weight Loss

Intervention: DRUG: VK2735 Oral

VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily

DRUG: Placebo Comparator

Placebo comparator administered orally once daily

Recruitment Status: NOT_YET_RECRUITING

Spo...